{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:57:36Z","timestamp":1793505456359,"version":"4.5.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The irreversible degeneration of dopamine neurons induced by \u03b1-synuclein (\u03b1-syn) aggregation in the substantia nigra is the central pathological feature of Parkinson's disease (PD). Neuroimaging and pathological autopsy studies consistently confirm significant iron accumulation in the brain of PD patients, suggesting a critical role for iron in disease progression. Current research has established that iron overload induces ferroptosis in dopaminergic neurons, evidence indicates that the impact of iron on PD pathology extends beyond ferroptosis. Iron also plays a regulatory role in modulating \u03b1-syn, affecting its aggregation, spatial conformation, post-translational modifications, and mRNA stability. Iron-induced \u03b1-syn aggregation can contribute to dopaminergic neurodegeneration through additional mechanisms, potentially creating a feedback loop in which \u03b1-syn further enhances iron accumulation, thus perpetuating a vicious cycle of neurotoxicity. Given \u03b1-syn\u2019s intrinsically disordered structure, targeting iron metabolism presents a promising therapeutic strategy for PD. Therefore, the development of iron chelators, alone or in combination with other therapeutic drugs, may offer a beneficial approach to alleviating PD symptoms and slowing disease progression.<\/jats:p>","DOI":"10.1186\/s10020-025-01208-3","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:13:36Z","timestamp":1745676816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["The interplay of iron, oxidative stress, and \u03b1-synuclein in Parkinson\u2019s disease progression"],"prefix":"10.1186","volume":"31","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Rosalind","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"1208_CR1","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1021\/jacs.8b02013","volume":"140","author":"DL Abeyawardhane","year":"2018","unstructured":"Abeyawardhane DL, et al. Iron redox chemistry promotes antiparallel oligomerization of alpha-synuclein. J Am Chem Soc. 2018;140:5028\u201332.","journal-title":"J Am Chem Soc"},{"key":"1208_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2024.103577","volume":"41","author":"E Alushaj","year":"2024","unstructured":"Alushaj E, et al. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson\u2019s disease: a 3T and 7T MRI study. Neuroimage Clin. 2024;41: 103577.","journal-title":"Neuroimage Clin"},{"key":"1208_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/biom8030067","volume":"8","author":"DM Angelova","year":"2018","unstructured":"Angelova DM, Brown DR. Model senescent microglia induce disease related changes in alpha-synuclein expression and activity. Biomolecules. 2018;8:67.","journal-title":"Biomolecules"},{"key":"1208_CR4","doi-asserted-by":"publisher","first-page":"11898","DOI":"10.1038\/s41598-022-15472-4","volume":"12","author":"D Atarod","year":"2022","unstructured":"Atarod D, et al. Bivalent metal ions induce formation of alpha-synuclein fibril polymorphs with different cytotoxicities. Sci Rep. 2022;12:11898.","journal-title":"Sci Rep"},{"key":"1208_CR5","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/mdc3.14161","volume":"11","author":"M Aubignat","year":"2024","unstructured":"Aubignat M, Tir M. Continuous Subcutaneous foslevodopa-foscarbidopa in Parkinson\u2019s disease: a mini-review of current scope and future outlook. Mov Disord Clin Pract. 2024;11:1188\u201394.","journal-title":"Mov Disord Clin Pract"},{"key":"1208_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.neurobiolaging.2014.10.026","volume":"36","author":"O Bar-Am","year":"2015","unstructured":"Bar-Am O, et al. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A\/monoamine oxidase-B inhibitor in animal models of Parkinson\u2019s disease and aging. Neurobiol Aging. 2015;36:1529\u201342.","journal-title":"Neurobiol Aging"},{"key":"1208_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1212\/WNL.45.1.182","volume":"45","author":"G Becker","year":"1995","unstructured":"Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson\u2019s disease visualized by transcranial color-coded real-time sonography. Neurology. 1995;45:182\u20134.","journal-title":"Neurology"},{"key":"1208_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/archneurol.2011.141","volume":"68","author":"D Berg","year":"2011","unstructured":"Berg D, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol. 2011;68:932\u20137.","journal-title":"Arch Neurol"},{"key":"1208_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neulet.2007.06.052","volume":"424","author":"ISS Bharathi","year":"2007","unstructured":"Bharathi ISS, Rao KS. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Neurosci Lett. 2007;424:78\u201382.","journal-title":"Neurosci Lett"},{"key":"1208_CR10","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1021\/acschemneuro.0c00196","volume":"11","author":"M Bi","year":"2020","unstructured":"Bi M, Du X, Jiao Q, Liu Z, Jiang H. alpha-synuclein regulates iron homeostasis via preventing Parkin-Mediated DMT1 ubiquitylation in Parkinson\u2019s disease models. ACS Chem Neurosci. 2020;11:1682\u201391.","journal-title":"ACS Chem Neurosci"},{"key":"1208_CR11","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1038\/s41467-021-26519-x","volume":"12","author":"S Bido","year":"2021","unstructured":"Bido S, et al. Microglia-specific overexpression of alpha-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. Nat Commun. 2021;12:6237.","journal-title":"Nat Commun"},{"key":"1208_CR12","doi-asserted-by":"publisher","first-page":"9893","DOI":"10.1021\/ja0618649","volume":"128","author":"A Binolfi","year":"2006","unstructured":"Binolfi A, et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc. 2006;128:9893\u2013901.","journal-title":"J Am Chem Soc"},{"key":"1208_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/biom10020195","volume":"10","author":"M Bisaglia","year":"2020","unstructured":"Bisaglia M, Bubacco L. Copper ions and Parkinson\u2019s disease: why is homeostasis so relevant? Biomolecules. 2020;10:195.","journal-title":"Biomolecules"},{"key":"1208_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.666585","volume":"9","author":"N Bisi","year":"2021","unstructured":"Bisi N, et al. alpha-synuclein: an all-inclusive trip around its structure, influencing factors and applied techniques. Front Chem. 2021;9: 666585.","journal-title":"Front Chem"},{"key":"1208_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, et al. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.","journal-title":"Cell Death Dis"},{"key":"1208_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1021\/acschemneuro.8b00390","volume":"10","author":"LL Chen","year":"2019","unstructured":"Chen LL, Huang YJ, Cui JT, Song N, Xie J. Iron dysregulation in Parkinson\u2019s disease: focused on the autophagy-lysosome pathway. ACS Chem Neurosci. 2019;10:863\u201371.","journal-title":"ACS Chem Neurosci"},{"key":"1208_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2019.104657","volume":"134","author":"YZ Ci","year":"2020","unstructured":"Ci YZ, et al. Iron overload induced by IRP2 gene knockout aggravates symptoms of Parkinson\u2019s disease. Neurochem Int. 2020;134: 104657.","journal-title":"Neurochem Int"},{"key":"1208_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-7-42","volume":"7","author":"KM Danzer","year":"2012","unstructured":"Danzer KM, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42.","journal-title":"Mol Neurodegener"},{"key":"1208_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/ars.2021.0218","volume":"37","author":"S David","year":"2022","unstructured":"David S, Jhelum P, Ryan F, Jeong SY, Kroner A. Dysregulation of iron homeostasis in the central nervous system and the role of ferroptosis in neurodegenerative disorders. Antioxid Redox Signal. 2022;37:150\u201370.","journal-title":"Antioxid Redox Signal"},{"key":"1208_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015814","volume":"6","author":"P Davies","year":"2011","unstructured":"Davies P, Moualla D, Brown DR. Alpha-synuclein is a cellular ferrireductase. PLoS ONE. 2011;6: e15814.","journal-title":"PLoS ONE"},{"key":"1208_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/ars.2015.6343","volume":"24","author":"E Deas","year":"2016","unstructured":"Deas E, et al. Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson\u2019s disease. Antioxid Redox Signal. 2016;24:376\u201391.","journal-title":"Antioxid Redox Signal"},{"key":"1208_CR22","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","volume":"387","author":"D Devos","year":"2022","unstructured":"Devos D, et al. Trial of deferiprone in Parkinson\u2019s disease. N Engl J Med. 2022;387:2045\u201355.","journal-title":"N Engl J Med"},{"key":"1208_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/1735-1995.181989","volume":"21","author":"FN Emamzadeh","year":"2016","unstructured":"Emamzadeh FN. Alpha-synuclein structure, functions, and interactions. J Res Med Sci. 2016;21:29.","journal-title":"J Res Med Sci"},{"key":"1208_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/WNR.0b013e328354a1f0","volume":"23","author":"F Febbraro","year":"2012","unstructured":"Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos MJN. \u03b1-Synuclein expression is modulated at the translational level by iron. NeuroReport. 2012;23:576\u201380.","journal-title":"NeuroReport"},{"key":"1208_CR25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1080\/15548627.2016.1190072","volume":"12","author":"B Fernandez","year":"2016","unstructured":"Fernandez B, et al. Iron overload causes endolysosomal deficits modulated by NAADP-regulated 2-pore channels and RAB7A. Autophagy. 2016;12:1487\u2013506.","journal-title":"Autophagy"},{"key":"1208_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/sj.mp.4001937","volume":"12","author":"AL Friedlich","year":"2007","unstructured":"Friedlich AL, Tanzi RE, Rogers JT. The 5\u2019-untranslated region of Parkinson\u2019s disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry. 2007;12:222\u20133.","journal-title":"Mol Psychiatry"},{"key":"1208_CR27","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1021\/acschemneuro.9b00527","volume":"11","author":"J Gallardo","year":"2020","unstructured":"Gallardo J, Escalona-Noguero C, Sot B. Role of alpha-synuclein regions in nucleation and elongation of amyloid fiber assembly. ACS Chem Neurosci. 2020;11:872\u20139.","journal-title":"ACS Chem Neurosci"},{"key":"1208_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167714","volume":"435","author":"V Gao","year":"2023","unstructured":"Gao V, Briano JA, Komer LE, Burre J. Functional and pathological effects of alpha-synuclein on synaptic SNARE complexes. J Mol Biol. 2023;435: 167714.","journal-title":"J Mol Biol"},{"key":"1208_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109617119","volume":"119","author":"SS Ghanem","year":"2022","unstructured":"Ghanem SS, et al. alpha-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc Natl Acad Sci USA. 2022;119: e2109617119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1208_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2017.04.004","volume":"154","author":"S Guhathakurta","year":"2017","unstructured":"Guhathakurta S, Bok E, Evangelista BA, Kim YS. Deregulation of alpha-synuclein in Parkinson\u2019s disease: insight from epigenetic structure and transcriptional regulation of SNCA. Prog Neurobiol. 2017;154:21\u201336.","journal-title":"Prog Neurobiol"},{"key":"1208_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-020-03369-x","volume":"12","author":"JJ Guo","year":"2021","unstructured":"Guo JJ, et al. Intranasal administration of alpha-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis. Cell Death Dis. 2021;12:81.","journal-title":"Cell Death Dis"},{"key":"1208_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/lifemeta\/loac035","volume":"1","author":"J Guo","year":"2022","unstructured":"Guo J, et al. Mitochondria as multifaceted regulators of ferroptosis. Life Metab. 2022;1:134\u201348.","journal-title":"Life Metab"},{"key":"1208_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s43188-022-00157-x","volume":"39","author":"S Ham","year":"2023","unstructured":"Ham S, Kim JH, Kim H, Shin JY, Lee Y. ATF4-activated parkin induction contributes to deferasirox-mediated cytoprotection in Parkinson\u2019s disease. Toxicol Res. 2023;39:191\u20139.","journal-title":"Toxicol Res"},{"key":"1208_CR34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/brain\/aww022","volume":"139","author":"DJ Hare","year":"2016","unstructured":"Hare DJ, Double KL. Iron and dopamine: a toxic couple. Brain. 2016;139:1026\u201335.","journal-title":"Brain"},{"key":"1208_CR35","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nrneurol.2015.100","volume":"11","author":"DJ Hare","year":"2015","unstructured":"Hare DJ, et al. Is early-life iron exposure critical in neurodegeneration? Nat Rev Neurol. 2015;11:536\u201344.","journal-title":"Nat Rev Neurol"},{"key":"1208_CR36","doi-asserted-by":"publisher","first-page":"9765","DOI":"10.1038\/s41598-022-13554-x","volume":"12","author":"P Haskova","year":"2022","unstructured":"Haskova P, et al. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Sci Rep. 2022;12:9765.","journal-title":"Sci Rep"},{"key":"1208_CR37","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","volume":"21","author":"S Hickman","year":"2018","unstructured":"Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21:1359\u201369.","journal-title":"Nat Neurosci"},{"key":"1208_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41598-021-04131-9","volume":"12","author":"M Hideshima","year":"2022","unstructured":"Hideshima M, et al. Two-step screening method to identify alpha-synuclein aggregation inhibitors for Parkinson\u2019s disease. Sci Rep. 2022;12:351.","journal-title":"Sci Rep"},{"key":"1208_CR39","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/antiox12030671","volume":"12","author":"BE Holbein","year":"2023","unstructured":"Holbein BE, Lehmann C. Dysregulated iron homeostasis as common disease etiology and promising therapeutic target. Antioxidants. 2023;12:671.","journal-title":"Antioxidants"},{"key":"1208_CR40","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.celrep.2018.01.089","volume":"22","author":"A Iannielli","year":"2018","unstructured":"Iannielli A, et al. Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson\u2019s disease models. Cell Rep. 2018;22:2066\u201379.","journal-title":"Cell Rep"},{"key":"1208_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.tcb.2024.01.010","volume":"34","author":"J Jacquemyn","year":"2024","unstructured":"Jacquemyn J, Ralhan I, Ioannou MS. Driving factors of neuronal ferroptosis. Trends Cell Biol. 2024;34:535\u201346.","journal-title":"Trends Cell Biol"},{"key":"1208_CR42","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1007\/s12035-021-02516-5","volume":"58","author":"Z Jansen van Rensburg","year":"2021","unstructured":"Jansen van Rensburg Z, Abrahams S, Bardien S, Kenyon C. Toxic feedback loop involving iron, reactive oxygen species, alpha-synuclein and neuromelanin in Parkinson\u2019s disease and intervention with turmeric. Mol Neurobiol. 2021;58:5920\u201336.","journal-title":"Mol Neurobiol"},{"key":"1208_CR43","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1002\/ana.410320714","volume":"32","author":"P Jenner","year":"1992","unstructured":"Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson\u2019s disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson\u2019s Disease Research Group. Ann Neurol. 1992;32:S82-87.","journal-title":"Ann Neurol"},{"key":"1208_CR44","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3233\/JAD-170601","volume":"61","author":"C Kaindlstorfer","year":"2018","unstructured":"Kaindlstorfer C, et al. The relevance of iron in the pathogenesis of multiple system atrophy: a viewpoint. J Alzheimers Dis. 2018;61:1253\u201373.","journal-title":"J Alzheimers Dis"},{"key":"1208_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1042\/bj20021525","volume":"371","author":"SV Kalivendi","year":"2003","unstructured":"Kalivendi SV, et al. 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem J. 2003;371:151\u201364.","journal-title":"Biochem J"},{"key":"1208_CR46","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.3390\/ijms23116216","volume":"23","author":"I Kawahata","year":"2022","unstructured":"Kawahata I, Finkelstein DI, Fukunaga K. Pathogenic impact of alpha-synuclein phosphorylation and its kinases in alpha-synucleinopathies. Int J Mol Sci. 2022;23:6216.","journal-title":"Int J Mol Sci"},{"key":"1208_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41531-023-00487-z","volume":"9","author":"C Kontaxi","year":"2023","unstructured":"Kontaxi C, Edwards RH. Synuclein phosphorylation: pathogenic or physiologic? NPJ Parkinsons Dis. 2023;9:47.","journal-title":"NPJ Parkinsons Dis"},{"key":"1208_CR48","doi-asserted-by":"publisher","first-page":"10992","DOI":"10.1074\/jbc.M709634200","volume":"283","author":"M Kostka","year":"2008","unstructured":"Kostka M, et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem. 2008;283:10992\u20131003.","journal-title":"J Biol Chem"},{"key":"1208_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116727","volume":"479","author":"S Kumfu","year":"2023","unstructured":"Kumfu S, et al. Ferroptosis inhibitor improves cardiac function more effectively than inhibitors of apoptosis and necroptosis through cardiac mitochondrial protection in rats with iron-overloaded cardiomyopathy. Toxicol Appl Pharmacol. 2023;479: 116727.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1208_CR50","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.biocel.2011.08.016","volume":"43","author":"T Kurz","year":"2011","unstructured":"Kurz T, Eaton JW, Brunk UT. The role of lysosomes in iron metabolism and recycling. Int J Biochem Cell Biol. 2011;43:1686\u201397.","journal-title":"Int J Biochem Cell Biol"},{"key":"1208_CR51","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.bbamcr.2015.01.021","volume":"1853","author":"DJ Lane","year":"2015","unstructured":"Lane DJ, et al. Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease. Biochim Biophys Acta. 2015;1853:1130\u201344.","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"1208_CR52","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/S1353-8020(13)70038-5","volume":"20","author":"W Le","year":"2014","unstructured":"Le W. Role of iron in UPS impairment model of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(Suppl 1):S158-161.","journal-title":"Parkinsonism Relat Disord"},{"key":"1208_CR53","doi-asserted-by":"publisher","first-page":"8783","DOI":"10.1038\/s41598-023-35975-y","volume":"13","author":"YH Leem","year":"2023","unstructured":"Leem YH, Kim DY, Park JE, Kim HS. Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and alpha-synuclein oligomerization in a subacute MPTP mouse model of Parkinson\u2019s disease. Sci Rep. 2023;13:8783.","journal-title":"Sci Rep"},{"key":"1208_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2024.109586","volume":"126","author":"YH Leem","year":"2024","unstructured":"Leem YH, Park JS, Park JE, Kim DY, Kim HS. Creatine supplementation with exercise reduces alpha-synuclein oligomerization and necroptosis in Parkinson\u2019s disease mouse model. J Nutr Biochem. 2024;126: 109586.","journal-title":"J Nutr Biochem"},{"key":"1208_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202409329","volume":"36","author":"L Lei","year":"2024","unstructured":"Lei L, et al. Targeting the labile iron pool with engineered DFO nanosheets to inhibit ferroptosis for Parkinson\u2019s disease therapy. Adv Mater. 2024;36: e2409329.","journal-title":"Adv Mater"},{"key":"1208_CR56","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s42003-021-02624-x","volume":"4","author":"ADG Leitao","year":"2021","unstructured":"Leitao ADG, et al. Selectivity of Lewy body protein interactions along the aggregation pathway of alpha-synuclein. Commun Biol. 2021;4:1124.","journal-title":"Commun Biol"},{"key":"1208_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JPD-2011-11040","volume":"1","author":"J Levin","year":"2011","unstructured":"Levin J, et al. Generation of ferric iron links oxidative stress to alpha-synuclein oligomer formation. J Parkinsons Dis. 2011;1:205\u201316.","journal-title":"J Parkinsons Dis"},{"key":"1208_CR58","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12264-010-1117-7","volume":"26","author":"WJ Li","year":"2010","unstructured":"Li WJ, Jiang H, Song N, Xie JX. Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells. Neurosci Bull. 2010;26:205\u201310.","journal-title":"Neurosci Bull"},{"key":"1208_CR59","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12640-010-9187-x","volume":"19","author":"W Li","year":"2011","unstructured":"Li W, Jiang H, Song N, Xie J. Oxidative stress partially contributes to iron-induced alpha-synuclein aggregation in SK-N-SH cells. Neurotox Res. 2011;19:435\u201342.","journal-title":"Neurotox Res"},{"key":"1208_CR60","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijbiomac.2020.06.274","volume":"163","author":"Y Li","year":"2020","unstructured":"Li Y, et al. Copper and iron ions accelerate the prion-like propagation of alpha-synuclein: a vicious cycle in Parkinson\u2019s disease. Int J Biol Macromol. 2020;163:562\u201373.","journal-title":"Int J Biol Macromol"},{"key":"1208_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719807","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Targeting microglial alpha-synuclein\/TLRs\/NF-kappaB\/NLRP3 inflammasome axis in Parkinson\u2019s disease. Front Immunol. 2021;12: 719807.","journal-title":"Front Immunol"},{"key":"1208_CR62","doi-asserted-by":"publisher","first-page":"8383","DOI":"10.3390\/molecules27238383","volume":"27","author":"Y Li","year":"2022","unstructured":"Li Y, Yu Y, Ma G. Modulation effects of Fe(3+), Zn(2+), and Cu(2+) ions on the amyloid fibrillation of alpha-synuclein: insights from a FTIR investigation. Molecules. 2022;27:8383.","journal-title":"Molecules"},{"key":"1208_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116633","volume":"230","author":"X Li","year":"2024","unstructured":"Li X, et al. Exploring heat shock proteins as therapeutic targets for Parkinson\u2019s disease. Biochem Pharmacol. 2024;230: 116633.","journal-title":"Biochem Pharmacol"},{"key":"1208_CR64","doi-asserted-by":"publisher","first-page":"175909142211332","DOI":"10.1177\/17590914221133236","volume":"14","author":"S Liu","year":"2022","unstructured":"Liu S, Gao X, Zhou S. New target for prevention and treatment of neuroinflammation: microglia iron accumulation and ferroptosis. ASN Neuro. 2022;14:17590914221133236.","journal-title":"ASN Neuro"},{"key":"1208_CR65","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/jphp.13109","volume":"71","author":"N Mannan Thodukayil","year":"2019","unstructured":"Mannan Thodukayil N, et al. Desferrioxamine and dextromethorphan combination exhibited synergistic effect and reversed the catalepsy behaviour in 6-hydroxydopamine hydroydopamine administered rats through regulating brain glutamate levels. J Pharm Pharmacol. 2019;71:1271\u201381.","journal-title":"J Pharm Pharmacol"},{"key":"1208_CR66","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1212\/01.wnl.0000286384.31050.b5","volume":"70","author":"WR Martin","year":"2008","unstructured":"Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology. 2008;70:1411\u20137.","journal-title":"Neurology"},{"key":"1208_CR67","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep. 2017;7:1398.","journal-title":"Sci Rep"},{"key":"1208_CR68","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00702-020-02149-3","volume":"127","author":"H Mochizuki","year":"2020","unstructured":"Mochizuki H, Choong CJ, Baba K. Parkinson\u2019s disease and iron. J Neural Transm (Vienna). 2020;127:181\u20137.","journal-title":"J Neural Transm (Vienna)"},{"key":"1208_CR69","doi-asserted-by":"publisher","first-page":"16293","DOI":"10.1038\/s41598-020-73207-9","volume":"10","author":"R Moons","year":"2020","unstructured":"Moons R, et al. Metal ions shape alpha-synuclein. Sci Rep. 2020;10:16293.","journal-title":"Sci Rep"},{"key":"1208_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2020.183536","volume":"1863","author":"G Musteikyte","year":"2021","unstructured":"Musteikyte G, et al. Interactions of alpha-synuclein oligomers with lipid membranes. Biochim Biophys Acta Biomembr. 2021;1863: 183536.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"1208_CR71","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fnins.2019.00180","volume":"13","author":"A Ndayisaba","year":"2019","unstructured":"Ndayisaba A, Kaindlstorfer C, Wenning GK. Iron in neurodegeneration - cause or consequence? Front Neurosci. 2019;13:180.","journal-title":"Front Neurosci"},{"key":"1208_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14607","volume":"30","author":"A Negida","year":"2024","unstructured":"Negida A, et al. Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson\u2019s disease: a systematic review and meta-analysis. CNS Neurosci Ther. 2024;30: e14607.","journal-title":"CNS Neurosci Ther"},{"key":"1208_CR73","first-page":"1","volume":"19","author":"B Oleg","year":"2018","unstructured":"Oleg B, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci. 2018;19:1.","journal-title":"Nat Rev Neurosci"},{"key":"1208_CR74","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41418-019-0408-4","volume":"27","author":"M Onate","year":"2020","unstructured":"Onate M, et al. The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease. Cell Death Differ. 2020;27:1169\u201385.","journal-title":"Cell Death Differ"},{"key":"1208_CR75","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","volume":"20","author":"N Ostrerova-Golts","year":"2000","unstructured":"Ostrerova-Golts N, et al. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci. 2000;20:6048\u201354.","journal-title":"J Neurosci"},{"key":"1208_CR76","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jinorgbio.2009.11.005","volume":"104","author":"Y Peng","year":"2010","unstructured":"Peng Y, Wang C, Xu HH, Liu YN, Zhou F. Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J Inorg Biochem. 2010;104:365\u201370.","journal-title":"J Inorg Biochem"},{"key":"1208_CR77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mcn.2014.08.002","volume":"62","author":"R Perfeito","year":"2014","unstructured":"Perfeito R, Lazaro DF, Outeiro TF, Rego AC. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells. Mol Cell Neurosci. 2014;62:51\u20139.","journal-title":"Mol Cell Neurosci"},{"key":"1208_CR78","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/biom11101508","volume":"11","author":"A Picca","year":"2021","unstructured":"Picca A, et al. Mitochondrial dysfunction, protein misfolding and neuroinflammation in Parkinson\u2019s disease: roads to biomarker discovery. Biomolecules. 2021;11:1508.","journal-title":"Biomolecules"},{"key":"1208_CR79","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fneur.2020.00366","volume":"11","author":"N Pyatigorskaya","year":"2020","unstructured":"Pyatigorskaya N, et al. Iron imaging as a diagnostic tool for Parkinson\u2019s disease: a systematic review and meta-analysis. Front Neurol. 2020;11:366.","journal-title":"Front Neurol"},{"key":"1208_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.135873","volume":"753","author":"K Raj","year":"2021","unstructured":"Raj K, Kaur P, Gupta GD, Singh S. Metals associated neurodegeneration in Parkinson\u2019s disease: insight to physiological, pathological mechanisms and management. Neurosci Lett. 2021;753: 135873.","journal-title":"Neurosci Lett"},{"key":"1208_CR81","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.tins.2024.05.005","volume":"47","author":"N Ramalingam","year":"2024","unstructured":"Ramalingam N, Haass C, Dettmer U. Physiological roles of alpha-synuclein serine-129 phosphorylation - not an oxymoron. Trends Neurosci. 2024;47:480\u201390.","journal-title":"Trends Neurosci"},{"key":"1208_CR82","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.tibs.2021.07.003","volume":"46","author":"F Rizzollo","year":"2021","unstructured":"Rizzollo F, More S, Vangheluwe P, Agostinis P. The lysosome as a master regulator of iron metabolism. Trends Biochem Sci. 2021;46:960\u201375.","journal-title":"Trends Biochem Sci"},{"key":"1208_CR83","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/ijms24010449","volume":"24","author":"L Rochette","year":"2022","unstructured":"Rochette L, et al. Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. 2022;24:449.","journal-title":"Int J Mol Sci"},{"key":"1208_CR84","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru Q, et al. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct Target Ther. 2024;9:271.","journal-title":"Signal Transduct Target Ther"},{"key":"1208_CR85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41593-022-01221-3","volume":"26","author":"SK Ryan","year":"2023","unstructured":"Ryan SK, et al. Microglia ferroptosis is regulated by SEC24B and contributes to neurodegeneration. Nat Neurosci. 2023;26:12\u201326.","journal-title":"Nat Neurosci"},{"key":"1208_CR86","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/cells10092452","volume":"10","author":"A Sarchione","year":"2021","unstructured":"Sarchione A, Marchand A, Taymans JM, Chartier-Harlin MC. Alpha-synuclein and lipids: the elephant in the room? Cells. 2021;10:2452.","journal-title":"Cells"},{"key":"1208_CR87","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1515\/revneuro-2012-0071","volume":"24","author":"H Sato","year":"2013","unstructured":"Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson\u2019s disease: a review of in vivo models. Rev Neurosci. 2013;24:115\u201323.","journal-title":"Rev Neurosci"},{"key":"1208_CR88","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41401-023-01153-z","volume":"45","author":"QQ Shen","year":"2024","unstructured":"Shen QQ, et al. Cell senescence induced by toxic interaction between alpha-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson\u2019s disease. Acta Pharmacol Sin. 2024;45:268\u201381.","journal-title":"Acta Pharmacol Sin"},{"key":"1208_CR89","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00702-020-02192-0","volume":"127","author":"J Sian-Hulsmann","year":"2020","unstructured":"Sian-Hulsmann J, Riederer P. The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson\u2019s disease. J Neural Transm. 2020;127:749\u201354.","journal-title":"J Neural Transm"},{"key":"1208_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168011","volume":"435","author":"RWL So","year":"2023","unstructured":"So RWL, Watts JC. alpha-synuclein conformational strains as drivers of phenotypic heterogeneity in neurodegenerative diseases. J Mol Biol. 2023;435: 168011.","journal-title":"J Mol Biol"},{"key":"1208_CR91","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1021\/acschemneuro.0c00557","volume":"11","author":"Y Sun","year":"2020","unstructured":"Sun Y, Pham AN, Hider RC, Zheng H, Waite TD. Effectiveness of the iron chelator CN128 in mitigating the formation of dopamine oxidation products associated with the progression of Parkinson\u2019s disease. ACS Chem Neurosci. 2020;11:3646\u201357.","journal-title":"ACS Chem Neurosci"},{"key":"1208_CR92","doi-asserted-by":"publisher","first-page":"R1292","DOI":"10.1016\/j.cub.2020.09.068","volume":"30","author":"D Tang","year":"2020","unstructured":"Tang D, Kroemer G. Ferroptosis. Curr Biol. 2020;30:R1292\u20137.","journal-title":"Curr Biol"},{"key":"1208_CR93","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","volume":"79","author":"GK Tofaris","year":"2022","unstructured":"Tofaris GK. Initiation and progression of alpha-synuclein pathology in Parkinson\u2019s disease. Cell Mol Life Sci. 2022;79:210.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"1208_CR94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2306682120","volume":"121","author":"Y Tong","year":"2024","unstructured":"Tong Y, Zhang P, Yang X, Liu X, Zhang J, Grudniewska M, Jung I, Abegg D, Liu J, Childs-Disney JL, Gibaut QM. Decreasing the intrinsically disordered protein \u03b1-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera. Proc Natl Acad Sci. 2024;121(2): e2306682120.","journal-title":"Proc Natl Acad Sci"},{"key":"1208_CR95","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/j.1742-4658.2012.08489.x","volume":"279","author":"IF Tsigelny","year":"2012","unstructured":"Tsigelny IF, et al. Role of alpha-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J. 2012;279:1000\u201313.","journal-title":"FEBS J"},{"key":"1208_CR96","doi-asserted-by":"publisher","first-page":"44284","DOI":"10.1074\/jbc.M105343200","volume":"276","author":"VN Uversky","year":"2001","unstructured":"Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson\u2019s disease and heavy metal exposure. J Biol Chem. 2001;276:44284\u201396.","journal-title":"J Biol Chem"},{"key":"1208_CR97","first-page":"D890","volume":"161","author":"MA van Schijndel","year":"2017","unstructured":"van Schijndel MA, et al. Medical Psychiatric Units in the Netherlands: an investigation into distribution and quality. Ned Tijdschr Geneeskd. 2017;161:D890.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1208_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2017.00001","volume":"8","author":"W Wan","year":"2017","unstructured":"Wan W, et al. Iron deposition leads to neuronal alpha-synuclein pathology by inducing autophagy dysfunction. Front Neurol. 2017;8:1.","journal-title":"Front Neurol"},{"key":"1208_CR99","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neuint.2019.02.016","volume":"125","author":"R Wang","year":"2019","unstructured":"Wang R, et al. Iron-induced oxidative stress contributes to alpha-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2. Neurochem Int. 2019;125:127\u201335.","journal-title":"Neurochem Int"},{"key":"1208_CR100","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1111\/jcmm.17946","volume":"27","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Iron-inhibited autophagy via transcription factor ZFP27 in Parkinson\u2019s disease. J Cell Mol Med. 2023;27:3614\u201327.","journal-title":"J Cell Mol Med"},{"key":"1208_CR101","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41420-024-02037-9","volume":"10","author":"S Wang","year":"2024","unstructured":"Wang S, Guo Q, Zhou L, Xia X. Ferroptosis: a double-edged sword. Cell Death Discov. 2024;10:265.","journal-title":"Cell Death Discov"},{"key":"1208_CR102","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1039\/C4MT00326H","volume":"7","author":"DG Workman","year":"2015","unstructured":"Workman DG, et al. Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson\u2019s with novel 1-hydroxypyridin-2-one metal chelators. Metallomics. 2015;7:867\u201376.","journal-title":"Metallomics"},{"key":"1208_CR103","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4103\/1673-5374.160108","volume":"10","author":"JR Wu","year":"2015","unstructured":"Wu JR, et al. Necrostatin-1 protection of dopaminergic neurons. Neural Regen Res. 2015;10:1120\u20134.","journal-title":"Neural Regen Res"},{"key":"1208_CR104","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.nbd.2017.05.001","volume":"104","author":"KC Wu","year":"2017","unstructured":"Wu KC, Liou HH, Kao YH, Lee CY, Lin CJ. The critical role of Nramp1 in degrading alpha-synuclein oligomers in microglia under iron overload condition. Neurobiol Dis. 2017;104:61\u201372.","journal-title":"Neurobiol Dis"},{"key":"1208_CR105","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jnc.14312","volume":"145","author":"Y Xiao","year":"2018","unstructured":"Xiao Y, et al. Iron promotes alpha-synuclein aggregation and transmission by inhibiting TFEB-mediated autophagosome-lysosome fusion. J Neurochem. 2018;145:34\u201350.","journal-title":"J Neurochem"},{"key":"1208_CR106","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jnc.13234","volume":"135","author":"Y Xu","year":"2015","unstructured":"Xu Y, Deng Y, Qing H. The phosphorylation of alpha-synuclein: development and implication for the mechanism and therapy of the Parkinson\u2019s disease. J Neurochem. 2015;135:4\u201318.","journal-title":"J Neurochem"},{"key":"1208_CR107","volume":"46","author":"T Xu","year":"2024","unstructured":"Xu T, et al. Disease burden of Parkinson\u2019s disease in China and its provinces from 1990 to 2021: findings from the global burden of disease study 2021. Lancet Reg Health West Pac. 2024;46: 101078.","journal-title":"Lancet Reg Health West Pac"},{"key":"1208_CR108","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bbrc.2020.07.025","volume":"531","author":"J Xue","year":"2020","unstructured":"Xue J, Wang HL, Xiao G. Transferrin1 modulates rotenone-induced Parkinson\u2019s disease through affecting iron homeostasis in Drosophila melanogaster. Biochem Biophys Res Commun. 2020;531:305\u201311.","journal-title":"Biochem Biophys Res Commun"},{"key":"1208_CR109","doi-asserted-by":"publisher","first-page":"5124553","DOI":"10.1155\/2022\/5124553","volume":"2022","author":"F Yan","year":"2022","unstructured":"Yan F, et al. Role of iron-related oxidative stress and mitochondrial dysfunction in cardiovascular diseases. Oxid Med Cell Longev. 2022;2022:5124553.","journal-title":"Oxid Med Cell Longev"},{"key":"1208_CR110","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1007\/s00330-023-10283-1","volume":"34","author":"S Yan","year":"2024","unstructured":"Yan S, et al. Spatiotemporal patterns of brain iron-oxygen metabolism in patients with Parkinson\u2019s disease. Eur Radiol. 2024;34:3074\u201383.","journal-title":"Eur Radiol"},{"key":"1208_CR111","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5483\/BMBRep.2022.55.7.073","volume":"55","author":"H Yoo","year":"2022","unstructured":"Yoo H, et al. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson\u2019s disease. BMB Rep. 2022;55:323\u201335.","journal-title":"BMB Rep"},{"key":"1208_CR112","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neuroscience.2014.09.071","volume":"284","author":"LH You","year":"2015","unstructured":"You LH, et al. Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson\u2019s disease. Neuroscience. 2015;284:234\u201346.","journal-title":"Neuroscience"},{"key":"1208_CR113","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1196\/annals.1306.025","volume":"1012","author":"MB Youdim","year":"2004","unstructured":"Youdim MB, Stephenson G, Ben SD. Ironing iron out in Parkinson\u2019s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004;1012:306\u201325.","journal-title":"Ann N Y Acad Sci"},{"key":"1208_CR114","doi-asserted-by":"publisher","first-page":"9843","DOI":"10.1073\/pnas.0403495101","volume":"101","author":"L Zecca","year":"2004","unstructured":"Zecca L, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA. 2004;101:9843\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1208_CR115","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s11064-021-03262-9","volume":"46","author":"X Zeng","year":"2021","unstructured":"Zeng X, et al. Benefits of iron chelators in the treatment of Parkinson\u2019s disease. Neurochem Res. 2021;46:1239\u201351.","journal-title":"Neurochem Res"},{"key":"1208_CR116","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s12035-013-8586-4","volume":"49","author":"W Zhang","year":"2014","unstructured":"Zhang W, et al. Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration. Mol Neurobiol. 2014;49:1153\u201365.","journal-title":"Mol Neurobiol"},{"key":"1208_CR117","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/aps.2017.49","volume":"38","author":"QS Zhang","year":"2017","unstructured":"Zhang QS, et al. Reassessment of subacute MPTP-treated mice as animal model of Parkinson\u2019s disease. Acta Pharmacol Sin. 2017;38:1317\u201328.","journal-title":"Acta Pharmacol Sin"},{"key":"1208_CR118","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.freeradbiomed.2020.03.015","volume":"152","author":"P Zhang","year":"2020","unstructured":"Zhang P, et al. Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson\u2019s disease. Free Radic Biol Med. 2020;152:227\u201334.","journal-title":"Free Radic Biol Med"},{"key":"1208_CR119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2011196118","volume":"118","author":"S Zhang","year":"2021","unstructured":"Zhang S, et al. Mechanistic basis for receptor-mediated pathological alpha-synuclein fibril cell-to-cell transmission in Parkinson\u2019s disease. Proc Natl Acad Sci U S A. 2021;118: e2011196118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1208_CR120","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s42003-022-03768-0","volume":"5","author":"C Zhang","year":"2022","unstructured":"Zhang C, et al. C-terminal truncation modulates alpha-Synuclein\u2019s cytotoxicity and aggregation by promoting the interactions with membrane and chaperone. Commun Biol. 2022;5:798.","journal-title":"Commun Biol"},{"key":"1208_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167680","volume":"435","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, et al. Structural insights of Fe(3+) induced alpha-synuclein fibrillation in Parkinson\u2019s disease. J Mol Biol. 2023;435: 167680.","journal-title":"J Mol Biol"},{"key":"1208_CR122","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13024-017-0218-4","volume":"12","author":"ZD Zhou","year":"2017","unstructured":"Zhou ZD, Tan EK. Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases. Mol Neurodegener. 2017;12:75.","journal-title":"Mol Neurodegener"},{"key":"1208_CR123","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbadis.2016.01.002","volume":"1862","author":"ZJ Zhu","year":"2016","unstructured":"Zhu ZJ, Wu KC, Yung WH, Qian ZM, Ke Y. Differential interaction between iron and mutant alpha-synuclein causes distinctive Parkinsonian phenotypes in Drosophila. Biochim Biophys Acta. 2016;1862:518\u201325.","journal-title":"Biochim Biophys Acta"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01208-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T15:02:25Z","timestamp":1745679745000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01208-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01208-3","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}